首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1700412篇
  免费   125240篇
  国内免费   3721篇
耳鼻咽喉   22205篇
儿科学   56614篇
妇产科学   47077篇
基础医学   241378篇
口腔科学   49307篇
临床医学   151324篇
内科学   332858篇
皮肤病学   38959篇
神经病学   131030篇
特种医学   64235篇
外国民族医学   246篇
外科学   259108篇
综合类   40522篇
一般理论   539篇
预防医学   124257篇
眼科学   40480篇
药学   123765篇
  7篇
中国医学   4361篇
肿瘤学   101101篇
  2019年   13332篇
  2018年   19665篇
  2017年   15069篇
  2016年   16478篇
  2015年   18785篇
  2014年   26170篇
  2013年   37929篇
  2012年   52760篇
  2011年   55454篇
  2010年   32759篇
  2009年   30676篇
  2008年   51581篇
  2007年   54851篇
  2006年   55291篇
  2005年   52626篇
  2004年   50780篇
  2003年   48111篇
  2002年   46301篇
  2001年   91714篇
  2000年   93470篇
  1999年   76614篇
  1998年   18778篇
  1997年   16270篇
  1996年   16418篇
  1995年   16638篇
  1994年   15229篇
  1993年   14000篇
  1992年   57316篇
  1991年   55257篇
  1990年   52929篇
  1989年   50718篇
  1988年   46110篇
  1987年   44923篇
  1986年   42198篇
  1985年   39981篇
  1984年   29312篇
  1983年   24846篇
  1982年   13842篇
  1981年   12326篇
  1979年   25469篇
  1978年   17526篇
  1977年   14842篇
  1976年   13799篇
  1975年   14489篇
  1974年   17581篇
  1973年   16888篇
  1972年   15644篇
  1971年   14426篇
  1970年   13410篇
  1969年   12490篇
排序方式: 共有10000条查询结果,搜索用时 62 毫秒
1.
Advances in biomarker-driven therapies for patients with nonsmall cell lung cancer (NSCLC) both provide opportunities to improve the treatment (and thus outcomes) for patients and pose new challenges for equitable care delivery. Over the last decade, the continuing development of new biomarker-driven therapies and evolving indications for their use have intensified the importance of interdisciplinary communication and coordination for patients with or suspected to have lung cancer. Multidisciplinary teams are challenged with completing comprehensive and timely biomarker testing and navigating the constantly evolving evidence base for a complex and time-sensitive disease. This guide provides context for the current state of comprehensive biomarker testing for NSCLC, reviews how biomarker testing integrates within the diagnostic continuum for patients, and illustrates best practices and common pitfalls that influence the success and timeliness of biomarker testing using a series of case scenarios.  相似文献   
2.
Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer is defined by the presence of the estrogen receptor and/or the progesterone receptor and the absence of HER2 gene amplification. HR-positive/HER2-negative breast cancer accounts for 65%–70% of all breast cancers, and incidence increases with increasing age. Treatment varies by stage, and endocrine therapy is the mainstay of treatment in both early stage and late-stage disease. Combinations with cyclin-dependent kinase 4/6 inhibitors have reduced distant recurrence in the early stage setting and improved overall survival in the metastatic setting. Chemotherapy is used based on stage and tumor biology in the early stage setting and after endocrine resistance for advanced disease. New therapies, including novel endocrine agents and antibody-drug conjugates, are now changing the treatment landscape. With the availability of new treatment options, it is important to define the optimal sequence of treatment to maximize clinical benefit while minimizing toxicity. In this review, the authors first discuss the pathologic and molecular features of HR-positive/HER2-negative breast cancer and mechanisms of endocrine resistance. Then, they discuss current and emerging therapies for both early stage and metastatic HR-positive/HER2-negative breast cancer, including treatment algorithms based on current data.  相似文献   
3.
4.
5.
6.
7.
8.
9.

Background

Advanced low-grade ovarian carcinoma (LGOC) is difficult to treat. In several studies, high estrogen receptor (ER) protein expression was observed in patients with LGOC, which suggests that antihormonal therapy (AHT) is a treatment option. However, only a subgroup of patients respond to AHT, and this response cannot be adequately predicted by currently used immunohistochemistry (IHC). A possible explanation is that IHC only takes the ligand, but not the activity, of the whole signal transduction pathway (STP) into account. Therefore, in this study, the authors assessed whether functional STP activity can be an alternative tool to predict response to AHT in LGOC.

Methods

Tumor tissue samples were obtained from patients with primary or recurrent LGOC who subsequently received AHT. Histoscores of ER and progesterone receptor (PR) were determined. In addition, STP activity of the ER STP and of six other STPs known to play a role in ovarian cancer was assessed and compared with the STP activity of healthy postmenopausal fallopian tube epithelium.

Results

Patients who had normal ER STP activity had a progression-free survival (PFS) of 16.1 months. This was significantly shorter in patients who had low and very high ER STP activity, with a median PFS of 6.0 and 2.1 months, respectively (p < .001). Unlike ER histoscores, PR histoscores were strongly correlated to the ER STP activity and thus to PFS.

Conclusions

Aberrant low and very high functional ER STP activity and low PR histoscores in patients with LGOC indicate decreased response to AHT. ER IHC is not representative of functional ER STP activity and is not related to PFS.  相似文献   
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号